OLYMPUSby New Odyssey
Menu
SEC registrant · CIK 0001473579

NANOMIX Corp

NANOMIX Corp (CIK 0001473579, EIN 27-0801073) reported revenue of $15,450 for FY2022 (2022-01-01 to 2022-12-31) and net income of -$12.33 million (-$12,332,976) for FY2022 (2022-01-01 to 2022-12-31), as filed in its 10-K filed 2023-04-07 (accession 0001213900-23-028171).

Figures are as filed with the SEC in XBRL, in whole US dollars unless stated, for the company's own fiscal years (fiscal year ends December 31).

Data as of Oct 21, 2026 (Olympus publication) · Markdown version

  • Values are as filed by the company in its 10-K and 10-Q XBRL data. When a later filing restates a value, the latest filed value is shown and the first reported value is noted.

Identifiers

As published in the company's EDGAR submissions record.

IdentifierValue
CIK0001473579
EIN27-0801073
SIC industry code2834 Pharmaceutical Preparations
State or country of incorporationDE
Fiscal year endDecember 31
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
Olympus entity IDorg_7495gvcm4japhyqyqjzfggf29b
  • The EIN is the one the filer gave to EDGAR. The SEC does not verify it; Olympus checks only that it has nine digits and a prefix the IRS assigns.

Latest annual financial metrics

The latest annual value of each standardised metric, with the filing it was taken from.

MetricValueFiscal periodPeriodFormFiledAccession numberXBRL concept
Revenue$15,450FY20222022-01-01 to 2022-12-3110-K2023-04-070001213900-23-028171Revenues
Net income-$12,332,976FY20222022-01-01 to 2022-12-3110-K2023-04-070001213900-23-028171ProfitLoss
Total assets$982,055FY2022as of 2022-12-3110-K2023-04-070001213900-23-028171Assets
Total liabilities$14,161,216FY2022as of 2022-12-3110-K2023-04-070001213900-23-028171Liabilities
Stockholders' equity-$13,832,692FY2022as of 2022-12-3110-K2023-04-070001213900-23-028171StockholdersEquity
Operating cash flow-$6,085,990FY20222022-01-01 to 2022-12-3110-K2023-04-070001213900-23-028171NetCashProvidedByUsedInOperatingActivities
Diluted earnings per share-$0.31 per shareFY20222022-01-01 to 2022-12-3110-K2023-04-070001213900-23-028171EarningsPerShareDiluted
Shares outstanding48,996,763 sharesFY2022as of 2023-04-0610-K2023-04-070001213900-23-028171EntityCommonStockSharesOutstanding
  • Accession numbers link to the filing's index on SEC EDGAR.

Revenue and net income history

Every annual revenue and net income value served for fiscal years 2013-2022, newest first, each with its filing.

MetricFiscal periodPeriodValueFormFiledAccession number
RevenueFY20222022-01-01 to 2022-12-31$15,45010-K2023-04-070001213900-23-028171
RevenueFY20212021-01-01 to 2021-12-31$141,77810-K2023-04-070001213900-23-028171
RevenueFY20202020-01-01 to 2020-12-31$513,24410-K2022-04-120001213900-22-019462
RevenueFY20192019-01-01 to 2019-12-31$16,32910-K2021-04-230001213900-21-022666
RevenueFY20182018-01-01 to 2018-12-31$31,72310-K2020-06-080001213900-20-014377
RevenueFY20172017-01-01 to 2017-12-31$29,35610-K2019-04-160001615774-19-005825
RevenueFY20162016-01-01 to 2016-12-31$98,87810-K2018-03-270001615774-18-002112
RevenueFY20152015-01-01 to 2015-12-31$98,94110-K2017-03-280001615774-17-001275
RevenueFY20142014-01-01 to 2014-12-31$199,58210-K2016-03-300001102624-16-002414
RevenueFY20132013-01-01 to 2013-12-31$323,41210-K2015-03-270001102624-15-000441
Net incomeFY20222022-01-01 to 2022-12-31-$12,332,97610-K2023-04-070001213900-23-028171
Net incomeFY20212021-01-01 to 2021-12-31-$9,465,03310-K2023-04-070001213900-23-028171
Net incomeFY20202020-01-01 to 2020-12-31-$907,88310-K2021-04-230001213900-21-022666
Net incomeFY20192019-01-01 to 2019-12-31-$3,694,07910-K2021-04-230001213900-21-022666
Net incomeFY20182018-01-01 to 2018-12-31-$3,601,21710-K2020-06-080001213900-20-014377
Net incomeFY20172017-01-01 to 2017-12-31-$1,584,87310-K2019-04-160001615774-19-005825
Net incomeFY20162016-01-01 to 2016-12-31-$3,737,52410-K2018-03-270001615774-18-002112
Net incomeFY20152015-01-01 to 2015-12-31-$2,489,81410-K2017-03-280001615774-17-001275
Net incomeFY20142014-01-01 to 2014-12-31-$4,699,93910-K2016-03-300001102624-16-002414
Net incomeFY20132013-01-01 to 2013-12-31-$1,484,11510-K2015-03-270001102624-15-000441
  • Revenue for FY2020 was restated: first reported as $9,336 (accession 0001213900-21-022666, filed 2021-04-23).
  • Net income for FY2013 was restated: first reported as -$4,601,503 (accession 0001102624-14-000379, filed 2014-03-14).

Recent 10-K and 10-Q filings

The 12 most recent 10-K, 10-Q and amendment filings in EDGAR, newest first.

FormFiledPeriod of reportAccession numberDocument
10-K2023-04-072022-12-310001213900-23-028171f10k2022_nanomixcorp.htm
10-Q2022-11-142022-09-300001213900-22-072212f10q0922_nanomixcorp.htm
10-Q2022-08-152022-06-300001213900-22-047962f10q0622_nanomixcorp.htm
10-Q2022-05-172022-03-310001213900-22-027556f10q0322_nanomixcorp.htm
10-K2022-04-122021-12-310001213900-22-019462f10k2021_nanomixcorp.htm
10-Q2021-11-152021-09-300001213900-21-059440f10q0921_bostontherap.htm
10-Q2021-10-052021-06-300001013762-21-000181f10q0621_bostonthera.htm
10-Q2021-06-142021-03-310001213900-21-032274f10q0321_bostontherapeutics.htm
10-K2021-04-232020-12-310001213900-21-022666f10k2020_bostontherapeutics.htm
10-Q2020-12-282020-09-300001213900-20-044605f10q0920_bostontherapeutics.htm
10-Q2020-12-172020-06-300001213900-20-043249f10q0620_bostontherap.htm
10-Q2020-11-302020-03-310001213900-20-039872f10q0320_bostontherapeutics.htm

Identifier registry

The company's identifiers in the Olympus identifier registry, each with how it was linked and its source.

SchemeValueHow linkedSourcePublished
SEC Central Index Key (CIK) · OLY-US-SEC-CIK0001473579published by the sourcedata.sec.gov/submissions/CIK0001473579.json2026-10-21
Employer Identification Number (EIN) · US-EIN27-0801073published by the sourcedata.sec.gov/submissions/CIK0001473579.json2026-10-21

Former names

NameFromTo
Boston Therapeutics, Inc.2010-03-082021-11-05
AVANYX Therapeutics, Inc.2010-02-082010-11-23

Sources

  • EDGAR submissions (nightly bulk archive) (company profile and filings) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:f7d2a4f18cb91aae, source date 2026-10-20. https://data.sec.gov/submissions/CIK0001473579.json
  • EDGAR XBRL company facts (nightly bulk archive) (financial metrics) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:01e4045aa34d7224, source date 2026-10-20. https://data.sec.gov/api/xbrl/companyfacts/CIK0001473579.json
  • Published by Olympus on Oct 21, 2026.
  • Source data: U.S. Securities and Exchange Commission (EDGAR). Values are as filed by the registrant; Olympus does not audit or adjust them.
  • Olympus is not affiliated with or endorsed by the U.S. Securities and Exchange Commission.

Get this data from the API

The same figures, with provenance on every value, from the API (free API key, reference) or from an AI agent through the Olympus MCP server.

curl
curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001473579" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001473579/financials" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001473579/filings?limit=12" -H "X-API-Key: $OLYMPUS_API_KEY"
MCP tool call
get_sec_company_financials {"cik":"1473579"}

On SEC EDGAR

About this data